ValuEngine upgraded shares of Bellicum Pharmaceuticals (NASDAQ:BLCM) from a strong sell rating to a sell rating in a report published on Wednesday.
A number of other brokerages have also weighed in on BLCM. Jefferies Group reissued a buy rating and issued a $16.00 price target on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. Zacks Investment Research raised shares of Bellicum Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, October 24th. Finally, Raymond James Financial reaffirmed a buy rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the stock. Bellicum Pharmaceuticals has a consensus rating of Hold and an average price target of $26.20.
Shares of Bellicum Pharmaceuticals (BLCM) opened at $9.42 on Wednesday. The company has a quick ratio of 6.08, a current ratio of 6.08 and a debt-to-equity ratio of 0.23. The firm has a market cap of $310.36, a P/E ratio of -3.15 and a beta of 1.18. Bellicum Pharmaceuticals has a fifty-two week low of $7.41 and a fifty-two week high of $15.55.
In other Bellicum Pharmaceuticals news, CFO Alan A. Musso sold 6,206 shares of Bellicum Pharmaceuticals stock in a transaction on Monday, November 27th. The shares were sold at an average price of $9.89, for a total transaction of $61,377.34. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Alan A. Musso sold 17,117 shares of Bellicum Pharmaceuticals stock in a transaction on Monday, December 11th. The stock was sold at an average price of $9.33, for a total transaction of $159,701.61. Following the sale, the chief financial officer now directly owns 31,585 shares of the company’s stock, valued at approximately $294,688.05. The disclosure for this sale can be found here. 18.77% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Voya Investment Management LLC bought a new position in shares of Bellicum Pharmaceuticals during the second quarter worth $132,000. Commonwealth Equity Services Inc bought a new position in shares of Bellicum Pharmaceuticals during the third quarter worth $142,000. Cubist Systematic Strategies LLC bought a new position in shares of Bellicum Pharmaceuticals during the third quarter worth $164,000. Nationwide Fund Advisors boosted its position in shares of Bellicum Pharmaceuticals by 30.4% during the second quarter. Nationwide Fund Advisors now owns 15,530 shares of the biopharmaceutical company’s stock worth $181,000 after purchasing an additional 3,620 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Bellicum Pharmaceuticals during the third quarter worth $189,000. 55.28% of the stock is currently owned by institutional investors.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
To view ValuEngine’s full report, visit ValuEngine’s official website.
What are top analysts saying about Bellicum Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bellicum Pharmaceuticals and related companies.